Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 21 Oct, 14:23 UTC

New follow-up results suggest Arcus’ drug might be superior to a marketed Merck medicine. Elsewhere, Eli Lilly and AstraZeneca forged new partnerships.